CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 80 enrolled
Drug / intervention
Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancerradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05291780
NCT05291780N/ACompleted
CompareCT.gov

STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-small Cell Lung Canter Patients Unfit for concurrEnt RAdio-chemotherapy

Radiotherapy Oncology Centre "Santa Maria" Hospital·interventional·Posted Mar 23, 2022·Updated Mar 23, 2022

In Brief

A clinical study evaluating Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer for Locally Advanced Lung Non-Small Cell Carcinoma. Completed, enrolled 80 participants across 1 site.

Detailed Summary

This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereoractic ablative radiotherapy (SABR) in selected unresectable newly diagnosed and recurrent locally advanced (LA) non-small cell lung cancer (NSCLC) patients unfit for concurrent chemo-radiotherapy (ChT-RT). Patients unfit for concurrent ChT-RT but fit for chemotherapy will be enrolled to sequential ChT-SABR; patients unfit for ChT will be enrolled to exclusive SABR.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced Lung Non-Small Cell Carcinoma
CountriesItaly
CollaboratorsPaola Anselmo,MD, Michelina Casale,PhD, Ernesto Maranzano,MD, Fabio Trippa,MD

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 23, 2022
Enrollment StartDec 1, 2015
Primary CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 4.3 years ago

Interventions

Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancerradiation

The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures. Participants will SABR once a day for 5 days, Monday through Friday (around 1 week).